Investments
Yazbeck & Co. (formerly Yazbeck Investments) was founded in 2008 to invest in asset-backed, cash-flowing opportunities, primarily real estate.
Early venture investments included seeding MyDx at a $5M valuation before it went public at $58M, and Ebbu at a $3M valuation before its 2018 acquisition by Canopy Growth for $330M. The firm exited its cannabis holdings by 2022.
After acquiring Laba International Trading Group, Yazbeck & Co. now invests across pharmaceuticals and healthcare, agriculture, advanced and sustainable technology, and real estate.
Active Investments
Antharis Therapeutics (2022)
Next-generation antibody-drug conjugates (ADCs) for cancer. Yazbeck & Co. brought together the investor group that put $43M into restructuring the company.
Elemental Biologics
Elemental Biologics is a biotechnology company developing monoclonal antibody therapies for immune-driven diseases involving chronic inflammation and immune dysregulation. These include autoimmune, inflammatory, and fibrotic diseases, as well as age-related inflammatory conditions with significant unmet medical need
Tillat Tillat Pharmaceuticals
Building a trusted global brand of medicines for a large, underserved patient population.
Exited Investments
MyDx
MyDx in 2013 – a leader in cannabis health technology tracking the science of how cannabis makes people feel. Mr. Yazbeck founded, seeded the capital for, took the company public, and successfully developed the product and created a market for the first handheld chemical analyzer for cannabis consumers
EBBU
Ebbu in 2014 – Yazbeck Investments was one of the first investors in Ebbu, a leader in hemp research acquired in 2018 for $330 million by Canopy Growth Corporation.
Policy Work
Lebanon Cannabis Legislation
(2018 to 2020)
Daniel Yazbeck worked closely with Lebanese government regulators, scientists, business leaders, and activists to help draft legislation legalizing medical cannabis. On April 21, 2020, Lebanon passed the law, legalizing medical cannabis cultivation in the country.
